 SAN DIEGO, July 21, 2021 PRNewswire -- Viracta Therapeutics, Inc. Nasdaq: VIRX, a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Food and Drug Administration FDA has cleared Viractas Investigational New Drug IND application to proceed into a Phase 1b2 trial in patients with EBV recurrent or metastatic nasopharyngeal carcinoma RM-NPC and other EBV solid tumors. The global Phase 1b2 trial is designed to evaluate the safety and preliminary efficacy of Viractas all-oral combination regimen in advanced EBV solid tumors including EBV RM-NPC, and in combination with the PD-1 inhibitor pembrolizumab in EBV RM-NPC. 